首页 > 最新文献

Discover. Oncology最新文献

英文 中文
Construction of an explainable machine learning model based on SHAP for predicting cardiovascular mortality risk among American cancer survivors. 构建基于SHAP的可解释机器学习模型,用于预测美国癌症幸存者的心血管死亡风险。
IF 2.9 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-02-11 DOI: 10.1007/s12672-026-04624-x
Xiaohe Shi, Yinliang Liu
{"title":"Construction of an explainable machine learning model based on SHAP for predicting cardiovascular mortality risk among American cancer survivors.","authors":"Xiaohe Shi, Yinliang Liu","doi":"10.1007/s12672-026-04624-x","DOIUrl":"https://doi.org/10.1007/s12672-026-04624-x","url":null,"abstract":"","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146156197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A composite immune-nutritional and tumor marker score predicts outcomes in LA-ESCC treated with neoadjuvant chemoimmunotherapy and surgery. 复合免疫营养和肿瘤标志物评分预测LA-ESCC接受新辅助化疗免疫治疗和手术治疗的结果。
IF 2.9 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-02-11 DOI: 10.1007/s12672-025-04378-y
Yiwei Fan, Jiang Zhou, Xiaotian Liu, Qianhe Ren, Shichun Lu, Weiguo Jin

Background: Neoadjuvant chemoimmunotherapy (nCIT) has improved outcomes in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC). However, accessible and reliable biomarkers to predict survival and pathological response remain limited. This study assessed the prognostic and predictive value of the Global Immune-Nutrition Index (GINI), cytokeratin-19 fragment (CYFRA 21 - 1), fibrinogen-albumin ratio index (FARI), and a composite score combining these markers-the GINI-CYFRA 21 - 1-FARI (GCF) score.

Methods: A retrospective analysis was conducted on 138 LA-ESCC patients who received nCIT followed by radical esophagectomy between 2021 and 2023. Optimal cut-off values for GINI, CYFRA 21 - 1, and FARI were determined using X-tile software. The composite GCF score was developed accordingly. Associations with disease-free survival (DFS) were evaluated using Kaplan-Meier analysis and multivariable Cox regression. Predictive performance was assessed via time-dependent ROC curves. Tumor regression grade (TRG) was analyzed using logistic regression, and a nomogram was constructed to predict pathological response.

Results: Elevated levels of GINI (median DFS: 20 vs. not estimable [NE] months; p = 0.001), CYFRA 21 - 1 (19 vs. NE months; p < 0.001), FARI (11 vs. 26 months; p < 0.001), and higher GCF scores (0 vs. 1 vs. ≥2: 18 vs. 22 vs. NE months; p < 0.001) were associated with worse DFS. The GCF score was independently predictive of DFS (low vs. high: HR = 0.264; p = 0.028) and demonstrated consistent discriminative capacity. For pathological response, the GCF score showed predictive value for TRG (AUC = 0.625; p = 0.004) and was independently associated with poor TRG (high vs. low: OR = 2.170; p = 0.048). A nomogram incorporating the GCF score outperformed models excluding it (AUC: 0.787 vs. 0.662; p < 0.05).

Conclusions: The GCF score-a composite of GINI, CYFRA 21 - 1, and FARI-independently predicts DFS and pathological response following nCIT and surgery in LA-ESCC, and may hold potential as a practical, blood-based biomarker. Its integration significantly enhances predictive model performance and may aid in individualized patient risk stratification.

背景:新辅助化疗免疫治疗(nCIT)改善了局部晚期食管鳞状细胞癌(LA-ESCC)患者的预后。然而,可用和可靠的生物标志物预测生存和病理反应仍然有限。本研究评估了全球免疫营养指数(GINI)、细胞角蛋白-19片段(CYFRA 21 -1)、纤维蛋白原-白蛋白比值指数(FARI)以及结合这些标志物的综合评分GINI-CYFRA 21 -1 -FARI (GCF)评分的预后和预测价值。方法:回顾性分析2021 - 2023年间138例接受nCIT并行根治性食管切除术的LA-ESCC患者。使用X-tile软件确定GINI、CYFRA 21 - 1和FARI的最佳临界值。综合GCF评分据此制定。使用Kaplan-Meier分析和多变量Cox回归评估与无病生存(DFS)的相关性。通过随时间变化的ROC曲线评估预测效果。采用logistic回归分析肿瘤消退等级(TRG),并构建nomogram预测病理反应。结果:GINI(中位DFS: 20 vs.不可估计[NE]个月;p = 0.001)、CYFRA 21 - 1 (19 vs. NE个月;p)水平升高。结论:GCF评分——GINI、CYFRA 21 - 1和fari的组合——独立预测了LA-ESCC在nCIT和手术后的DFS和病理反应,并可能成为一种实用的、基于血液的生物标志物。其集成显著提高了预测模型的性能,并可能有助于个体化患者风险分层。
{"title":"A composite immune-nutritional and tumor marker score predicts outcomes in LA-ESCC treated with neoadjuvant chemoimmunotherapy and surgery.","authors":"Yiwei Fan, Jiang Zhou, Xiaotian Liu, Qianhe Ren, Shichun Lu, Weiguo Jin","doi":"10.1007/s12672-025-04378-y","DOIUrl":"https://doi.org/10.1007/s12672-025-04378-y","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant chemoimmunotherapy (nCIT) has improved outcomes in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC). However, accessible and reliable biomarkers to predict survival and pathological response remain limited. This study assessed the prognostic and predictive value of the Global Immune-Nutrition Index (GINI), cytokeratin-19 fragment (CYFRA 21 - 1), fibrinogen-albumin ratio index (FARI), and a composite score combining these markers-the GINI-CYFRA 21 - 1-FARI (GCF) score.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 138 LA-ESCC patients who received nCIT followed by radical esophagectomy between 2021 and 2023. Optimal cut-off values for GINI, CYFRA 21 - 1, and FARI were determined using X-tile software. The composite GCF score was developed accordingly. Associations with disease-free survival (DFS) were evaluated using Kaplan-Meier analysis and multivariable Cox regression. Predictive performance was assessed via time-dependent ROC curves. Tumor regression grade (TRG) was analyzed using logistic regression, and a nomogram was constructed to predict pathological response.</p><p><strong>Results: </strong>Elevated levels of GINI (median DFS: 20 vs. not estimable [NE] months; p = 0.001), CYFRA 21 - 1 (19 vs. NE months; p < 0.001), FARI (11 vs. 26 months; p < 0.001), and higher GCF scores (0 vs. 1 vs. ≥2: 18 vs. 22 vs. NE months; p < 0.001) were associated with worse DFS. The GCF score was independently predictive of DFS (low vs. high: HR = 0.264; p = 0.028) and demonstrated consistent discriminative capacity. For pathological response, the GCF score showed predictive value for TRG (AUC = 0.625; p = 0.004) and was independently associated with poor TRG (high vs. low: OR = 2.170; p = 0.048). A nomogram incorporating the GCF score outperformed models excluding it (AUC: 0.787 vs. 0.662; p < 0.05).</p><p><strong>Conclusions: </strong>The GCF score-a composite of GINI, CYFRA 21 - 1, and FARI-independently predicts DFS and pathological response following nCIT and surgery in LA-ESCC, and may hold potential as a practical, blood-based biomarker. Its integration significantly enhances predictive model performance and may aid in individualized patient risk stratification.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146156096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic targeting of cancer stem cell-specific surface glycans and glycoproteins. 肿瘤干细胞特异性表面聚糖和糖蛋白的靶向治疗。
IF 2.9 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-02-11 DOI: 10.1007/s12672-026-04586-0
Mutaz Jamal Al-Khreisat, Waleed K Abdulsahib, Ihsan Khudhair Jasim, H Malathi, Priya Priyadarshini Nayak, D Alex Anand, Gunjan Mukherjee, Aashna Sinha, Gulsara Ruziyeva
{"title":"Therapeutic targeting of cancer stem cell-specific surface glycans and glycoproteins.","authors":"Mutaz Jamal Al-Khreisat, Waleed K Abdulsahib, Ihsan Khudhair Jasim, H Malathi, Priya Priyadarshini Nayak, D Alex Anand, Gunjan Mukherjee, Aashna Sinha, Gulsara Ruziyeva","doi":"10.1007/s12672-026-04586-0","DOIUrl":"https://doi.org/10.1007/s12672-026-04586-0","url":null,"abstract":"","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146156324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precision management of cervical cancer emphasizes immunotherapy combination regimens and translational advances. 宫颈癌的精确管理强调免疫治疗联合方案和转化进展。
IF 2.9 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-02-11 DOI: 10.1007/s12672-026-04588-y
Huan Shi, Xinyun Huang, Jie Yu, Weiyan Shan, Jingxia Zhang, Qiaoping Xu, Hongkai Shang
{"title":"Precision management of cervical cancer emphasizes immunotherapy combination regimens and translational advances.","authors":"Huan Shi, Xinyun Huang, Jie Yu, Weiyan Shan, Jingxia Zhang, Qiaoping Xu, Hongkai Shang","doi":"10.1007/s12672-026-04588-y","DOIUrl":"https://doi.org/10.1007/s12672-026-04588-y","url":null,"abstract":"","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146156241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and validation of an oxidative phosphorylation based prognostic model revealing tumor progression and immune microenvironment in lung adenocarcinoma. 基于氧化磷酸化的肺腺癌预后模型的建立和验证,揭示肿瘤进展和免疫微环境。
IF 2.9 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-02-11 DOI: 10.1007/s12672-026-04478-3
Hongxia Ma, Shaoshan Zeng, Changping Xie, Chengcheng Gao, Siao Jiang, Liuxin Chen, Wenhao Tian, Lizhi Huang

Background: Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality worldwide. Although oxidative phosphorylation (OXPHOS) has been linked to tumor progression, its prognostic significance and underlying mechanisms in LUAD remain unclear.

Methods: RNA-seq data from TCGA were used as the discovery cohort, and multiple GEO datasets were used for independent validation. OXPHOS-related genes were obtained from MitoCarta3.0. Prognostic biomarkers were selected by LASSO-Cox regression. Immune cell infiltration was estimated using CIBERSORT and ssGSEA. Single-cell RNA-seq data were analyzed to examine biomarker expression, pathway enrichment, and cell-cell communication.

Results: Thirteen OXPHOS-associated genes were used to construct a prognostic model with robust predictive performance. Model performance was validated across independent cohorts and demonstrated reliable prognostic value. Higher risk scores correlated with poorer overall survival and reduced immune infiltration. UQCC3⁺ and RAB5IF⁺ epithelial cells were enriched in E2F target and G2M checkpoint pathways and showed enhanced interactions via TGF-β and Galectin signaling.

Conclusions: We present an OXPHOS-based prognostic model for LUAD. OXPHOS reprogramming, particularly involving UQCC3 and RAB5IF in epithelial cells, may promote malignant proliferation and immunosuppression. These findings provide novel prognostic biomarkers and potential therapeutic targets, which may support personalized treatment strategies and guide future translational studies.

背景:肺腺癌(LUAD)仍然是世界范围内癌症死亡的主要原因。虽然氧化磷酸化(OXPHOS)与肿瘤进展有关,但其在LUAD中的预后意义和潜在机制尚不清楚。方法:使用TCGA的RNA-seq数据作为发现队列,并使用多个GEO数据集进行独立验证。从MitoCarta3.0中获得oxphos相关基因。采用LASSO-Cox回归选择预后生物标志物。使用CIBERSORT和ssGSEA评估免疫细胞浸润。分析单细胞RNA-seq数据以检测生物标志物表达、通路富集和细胞间通讯。结果:13个oxphos相关基因被用于构建具有可靠预测性能的预后模型。在独立队列中验证了模型的性能,并证明了可靠的预后价值。较高的风险评分与较差的总生存率和免疫浸润减少相关。UQCC3 +和RAB5IF +在上皮细胞中富集了E2F靶点和G2M检查点通路,并通过TGF-β和Galectin信号通路表现出增强的相互作用。结论:我们提出了一种基于oxphos的LUAD预后模型。OXPHOS重编程,特别是涉及上皮细胞中的UQCC3和RAB5IF,可能促进恶性增殖和免疫抑制。这些发现提供了新的预后生物标志物和潜在的治疗靶点,可能支持个性化治疗策略并指导未来的转化研究。
{"title":"Development and validation of an oxidative phosphorylation based prognostic model revealing tumor progression and immune microenvironment in lung adenocarcinoma.","authors":"Hongxia Ma, Shaoshan Zeng, Changping Xie, Chengcheng Gao, Siao Jiang, Liuxin Chen, Wenhao Tian, Lizhi Huang","doi":"10.1007/s12672-026-04478-3","DOIUrl":"https://doi.org/10.1007/s12672-026-04478-3","url":null,"abstract":"<p><strong>Background: </strong>Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality worldwide. Although oxidative phosphorylation (OXPHOS) has been linked to tumor progression, its prognostic significance and underlying mechanisms in LUAD remain unclear.</p><p><strong>Methods: </strong>RNA-seq data from TCGA were used as the discovery cohort, and multiple GEO datasets were used for independent validation. OXPHOS-related genes were obtained from MitoCarta3.0. Prognostic biomarkers were selected by LASSO-Cox regression. Immune cell infiltration was estimated using CIBERSORT and ssGSEA. Single-cell RNA-seq data were analyzed to examine biomarker expression, pathway enrichment, and cell-cell communication.</p><p><strong>Results: </strong>Thirteen OXPHOS-associated genes were used to construct a prognostic model with robust predictive performance. Model performance was validated across independent cohorts and demonstrated reliable prognostic value. Higher risk scores correlated with poorer overall survival and reduced immune infiltration. UQCC3⁺ and RAB5IF⁺ epithelial cells were enriched in E2F target and G2M checkpoint pathways and showed enhanced interactions via TGF-β and Galectin signaling.</p><p><strong>Conclusions: </strong>We present an OXPHOS-based prognostic model for LUAD. OXPHOS reprogramming, particularly involving UQCC3 and RAB5IF in epithelial cells, may promote malignant proliferation and immunosuppression. These findings provide novel prognostic biomarkers and potential therapeutic targets, which may support personalized treatment strategies and guide future translational studies.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146156290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bibliometric analysis reveals the current status and future trends of cancer associated photodynamic therapy in breast cancer. 文献计量学分析揭示了乳腺癌相关光动力治疗的现状和未来趋势。
IF 2.9 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-02-10 DOI: 10.1007/s12672-026-04632-x
Jinxiu Xie, Siying Chen, Shaoyu Fu, Jiayi Rao, Chenxi Wang, Yan Xiao, Kang Zou
{"title":"Bibliometric analysis reveals the current status and future trends of cancer associated photodynamic therapy in breast cancer.","authors":"Jinxiu Xie, Siying Chen, Shaoyu Fu, Jiayi Rao, Chenxi Wang, Yan Xiao, Kang Zou","doi":"10.1007/s12672-026-04632-x","DOIUrl":"https://doi.org/10.1007/s12672-026-04632-x","url":null,"abstract":"","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146156190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Obstacles and improvement strategies for CAR-T cell therapy in solid tumors. CAR-T细胞治疗实体瘤的障碍和改进策略。
IF 2.9 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-02-10 DOI: 10.1007/s12672-026-04473-8
Zhihao Luo, Qian Hu, Meng Ren, Li Wang, Qingshuang Zou, Xiaosha Wen, Shang Chen, Quan Liu, Dixian Luo, Zifen Guo
{"title":"Obstacles and improvement strategies for CAR-T cell therapy in solid tumors.","authors":"Zhihao Luo, Qian Hu, Meng Ren, Li Wang, Qingshuang Zou, Xiaosha Wen, Shang Chen, Quan Liu, Dixian Luo, Zifen Guo","doi":"10.1007/s12672-026-04473-8","DOIUrl":"10.1007/s12672-026-04473-8","url":null,"abstract":"","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"17 1","pages":"271"},"PeriodicalIF":2.9,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146149470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune-related LncRNA signatures define tumor microenvironment subtypes and predict immunotherapy response in NSCLC. 免疫相关LncRNA特征定义肿瘤微环境亚型并预测非小细胞肺癌的免疫治疗反应。
IF 2.9 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-02-10 DOI: 10.1007/s12672-026-04429-y
Ang Li, Yutao Pang, Xiao Yang, Hongfei Zhang, Dong Wu, Liyao Lin, Zhan He, Zhu Liang, Jie Chen, Fasheng Li
{"title":"Immune-related LncRNA signatures define tumor microenvironment subtypes and predict immunotherapy response in NSCLC.","authors":"Ang Li, Yutao Pang, Xiao Yang, Hongfei Zhang, Dong Wu, Liyao Lin, Zhan He, Zhu Liang, Jie Chen, Fasheng Li","doi":"10.1007/s12672-026-04429-y","DOIUrl":"https://doi.org/10.1007/s12672-026-04429-y","url":null,"abstract":"","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"17 1","pages":"272"},"PeriodicalIF":2.9,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146156320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bidirectional Mendelian randomization identifies differential causal associations between inflammatory cytokines and lung cancer subtypes. 双向孟德尔随机化确定炎症细胞因子和肺癌亚型之间的差异因果关系。
IF 2.9 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-02-10 DOI: 10.1007/s12672-026-04615-y
Menglu Sun, Xue Gao
{"title":"Bidirectional Mendelian randomization identifies differential causal associations between inflammatory cytokines and lung cancer subtypes.","authors":"Menglu Sun, Xue Gao","doi":"10.1007/s12672-026-04615-y","DOIUrl":"https://doi.org/10.1007/s12672-026-04615-y","url":null,"abstract":"","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146149348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical efficacy and cardiac toxicity associated with first-line dabrafenib plus trametinib in advanced BRAF V600_K601delinsE-mutated lung adenocarcinoma: a case report and literature review. 一线达非尼加曲美替尼治疗晚期BRAF v600_k601delinse突变肺腺癌的临床疗效及心脏毒性:1例报告及文献复习
IF 2.9 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-02-10 DOI: 10.1007/s12672-026-04607-y
Lu Yang, Xuanjun Liu, Xiang Zhu, Baoshan Cao, Yangchun Gu, Wei Liu
{"title":"Clinical efficacy and cardiac toxicity associated with first-line dabrafenib plus trametinib in advanced BRAF V600_K601delinsE-mutated lung adenocarcinoma: a case report and literature review.","authors":"Lu Yang, Xuanjun Liu, Xiang Zhu, Baoshan Cao, Yangchun Gu, Wei Liu","doi":"10.1007/s12672-026-04607-y","DOIUrl":"https://doi.org/10.1007/s12672-026-04607-y","url":null,"abstract":"","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146149351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Discover. Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1